Certain populations are at higher risk of experiencing toxic effects from pyrazinamide. These include elderly patients, those with pre-existing liver or kidney disease, and individuals with gout. Additionally, genetic polymorphisms affecting drug metabolism may predispose some individuals to increased toxicity.
